BiotechTube

zetomipzomib + placebo

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lupus Nephritis

Conditions

Lupus Nephritis

Trial Timeline

Nov 3, 2023 → Nov 8, 2024

NCT ID
NCT05781750

About zetomipzomib + placebo

zetomipzomib + placebo is a phase 2 stage product being developed by Kezar Life Sciences for Lupus Nephritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT05781750. Target conditions include Lupus Nephritis.

What happened to similar drugs?

8 of 20 similar drugs in Lupus Nephritis were approved

Approved (8) Terminated (7) Active (7)
✅tacrolimusAstellas PharmaApproved
✅Rosuvastatin + SimvastatinAstraZenecaApproved
✅AnifrolumabAstraZenecaApproved
✅BMS-986165Bristol Myers SquibbApproved
✅versus hydroxychloroquineSanofiApproved
✅Belimumab plus Early Vaccination + Belimumab plus Late VaccinationGSK plcApproved
✅Placebo plus standard therapy + Belimumab 10 mg/kg plus standard therapy + Standard therapyGSK plcApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05781750Phase 2Terminated

Competing Products

20 competing products in Lupus Nephritis

See all competitors
ProductCompanyStageHype Score
Tabalumab Auto-Injector + Tabalumab Prefilled SyringeEli LillyPhase 3
32
Baricitinib + PlaceboEli LillyPhase 2
35
DS-7011a + PlaceboDaiichi SankyoPhase 1
29
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
32
tacrolimusAstellas PharmaPhase 3
40
TacrolimusAstellas PharmaPre-clinical
26
tacrolimus capsule + tacrolimus placebo + leflunomide tablet + leflunomide placebo + prednisoneAstellas PharmaPhase 3
32
tacrolimusAstellas PharmaApproved
35
Tacrolimus capsules + Cyclophosphamide injections + PrednisoneAstellas PharmaPhase 3
40
E6742EisaiPhase 1/2
32
Baricitinib + PlaceboEli LillyPhase 3
40
Baricitinib + PlaceboEli LillyPhase 3
32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
40
LY3361237 + PlaceboEli LillyPhase 2
27
LY2127399 + PlaceboEli LillyPhase 3
32
LY3361237 + PlaceboEli LillyPhase 1
29
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeksEli LillyPhase 3
40
Baricitinib + PlaceboEli LillyPhase 3
32
LY3471851 + PlaceboEli LillyPhase 1
29
LY3471851 + PlaceboEli LillyPhase 2
35